ArticleLiver cancer2017
Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.
Article in Liver cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.PloS one · 2020Trial
- The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.Frontiers in oncology · 2021Review
- LncRNA NKILA Promotes Epithelial-Mesenchymal Transition of Liver Cancer Cells by Targeting miR-485-5p.Journal of oncology · 2021Article
- Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.Liver cancer · 2019Article
- Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.Liver cancer · 2019Article
- Pembrolizumab for the Treatment of Hepatocellular Carcinoma.Liver cancer · 2019Article
- Cabozantinib for advanced hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2019Article
- Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.World journal of gastroenterology · 2019Review
- Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma.Liver cancer · 2019Article
- Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial.Liver cancer · 2018Article
- Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma.Liver cancer · 2018Article
- Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.Liver cancer · 2018Article
- Combination Cancer Immunotherapy in Hepatocellular Carcinoma.Liver cancer · 2018Article
- Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review.Oncotarget · 2017Article
- Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials.Liver cancer · 2017Article
- Lenvatinib in Advanced Hepatocellular Carcinoma.Liver cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.